Cargando…

P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION

Detalles Bibliográficos
Autores principales:	Jentzsch, Madlen, Bischof, Lara, Ussmann, Jule, Brauer, Dominic, Backhaus, Donata, Pham Thanh, Tung, Franke, Georg-Nikolaus, Vucinic, Vladan, Platzbecker, Uwe, Schwind, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428976/ http://dx.doi.org/10.1097/01.HS9.0000968896.85830.01

Ejemplares similares

Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission
por: Jentzsch, Madlen, et al.
Publicado: (2022)

P508: THE PROGNOSTIC SIGNIFICANCE OF THE MEASURABLE RESIDUAL DISEASE STATUS WITHIN THE THREE AML ELN2022 RISK GROUPS
por: Bischof, Lara, et al.
Publicado: (2023)

PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
por: Ussmann, Jule, et al.
Publicado: (2023)

Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2023)

Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2022)

P1315: THE CHRONOLOGICAL SEQUENCE OF 12 GY TOTAL BODY IRRADIATION AND CYCLOPHOSPHAMIDE CONDITIONING DOES NOT IMPACT OUTCOMES IN AML PATIENTS UNDERGOING MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
por: Franke, Georg-Nikolaus, et al.
Publicado: (2023)

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
por: Backhaus, Donata, et al.
Publicado: (2021)

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
por: Bill, Marius, et al.
Publicado: (2022)

A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older
por: Backhaus, Donata, et al.
Publicado: (2022)

Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2021)

Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell Transplantation
por: Brauer, Dominic, et al.
Publicado: (2021)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

P1313: PREDICTING OUTCOMES IN AML PATIENTS CONSOLIDATED BY AN ALLOGENEIC STEM CELL TRANSPLANTATION USING THE KNOWLEDGE BANK APPROACH
por: Jentzsch, M., et al.
Publicado: (2022)

Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML
por: Georgi, Julia-Annabell, et al.
Publicado: (2022)

Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2021)

P1381: EARLY FULL DONOR CHIMERISM AFTER FLAMSA RIC BASED ALLOGENEIC HSCT BUT NOT PRESENCE OF MORPHOLOGICAL REMISSION ASSOCIATES WITH OUTCOMES IN R/R AML PATIENTS
por: Ussmann, J., et al.
Publicado: (2022)

S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia
por: Vucinic, Vladan, et al.
Publicado: (2021)

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
por: Lambert, Juliette, et al.
Publicado: (2014)

The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively
por: Heiblig, Maël, et al.
Publicado: (2021)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

P1356: PATIENT-SPECIFIC DIGITAL DROPLET PCR ASSAYS FOR MINIMAL RESIDUAL DISEASE DETECTION OF RUNX1 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
por: Jentzsch, M., et al.
Publicado: (2022)

ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML
por: Jentzsch, Madlen, et al.
Publicado: (2020)

PB1762: A NEW MONOCLONAL ANTIBODY PROVIDES INSIGHTS ON NPM1 MUTANT SUBCELLULAR EXPRESSION, INTRACLONAL CELL DIFFERENTIATION AND MRD IN NPM1-MUTATED AML
por: Falini, Brunangelo, et al.
Publicado: (2023)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

MRD Tailored Therapy in AML: What We Have Learned So Far
por: Ngai, Lok Lam, et al.
Publicado: (2021)

MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?
por: Pessach, Ilias, et al.
Publicado: (2022)

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
por: Meddi, Elisa, et al.
Publicado: (2023)

Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome
por: Franke, Georg-Nikolaus, et al.
Publicado: (2021)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review
por: Teixeira, Alexandra, et al.
Publicado: (2023)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
por: Tiong, Ing S., et al.
Publicado: (2023)

Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest
por: Nachmias, Boaz, et al.
Publicado: (2023)

High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation with the CD34(+)/CD38(-) population
por: Jentzsch, Madlen, et al.
Publicado: (2020)

AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML
por: Hanekamp, Diana, et al.
Publicado: (2021)

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
por: Othman, Jad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q883umtmqujn0lsjqsqmqm22r4